Using letermovir to prevent CMV infection in kidney and pancreas transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of letermovir in preventing the recurrence of cytomegalovirus (CMV) infection in adult kidney and simultaneous kidney/pancreas transplant recipients who are at high risk for CMV. Participants will switch from ganciclovir derivatives to letermovir once their viral load is below a specified threshold, allowing for reduced exposure to ganciclovir and its associated side effects. The primary goal is to determine if letermovir can decrease the duration of ganciclovir treatment and the incidence of recurrent CMV viremia. The study will last approximately six months and involves close monitoring of viral loads.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* undergone kidney or simultaneous kidney/pancreas transplant
* high-risk CMV serostatus (D+/R-) at time of transplant
* develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
* demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
* able to provide informed consent to participate

Exclusion Criteria:

* contraindication to letermovir or its excipients
* develop ganciclovir-resistant CMV infection
* currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
* unable or unwilling, in the opinion of the Investigator, to comply with the protocol
* pregnant or breastfeeding

Where it's running

• UW Hospital and Clinics
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Sandesh Parajuli, MBBS — University of Wisconsin, Madison
• Study coordinator: Sandesh Parajuli, MBBS
• Email: sparajuli@medicine.wisc.edu
• Phone: (608) 262-2122

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Long-term health of children born to mothers who had a solid organ transplant

  This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT07291258

• Family-donor viral CTLs plus standard care vs standard care alone for refractory ADV or CMV infection after stem cell transplant

  This study tests whether using family-donor virus-specific CTLs in addition to usual treatment helps children, teens, and young adults with hard-to-treat CMV or adenovirus infections after a stem cell transplant.

  Recruiting Phase 3 New York Medical College · Valhalla, New York and 1 other locations · NCT07225972

• CMV-specific immunoglobulin to prevent CMV problems in children getting allogeneic stem cell transplants

  Doctors will try giving CMV-specific immunoglobulin to children having allogeneic stem cell transplants to prevent CMV reactivation and related transplant complications.

  Recruiting University of Pisa · Trieste · NCT07013370

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.